story of the week
Long-Term Follow-Up of Mosunetuzumab in Patients With Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
J. Clin. Oncol 2024 Mar 28;[EPub Ahead of Print], LE Budde, S Assouline, LH Sehn, SJ Schuster, SS Yoon, DH Yoon, MJ Matasar, F Bosch, WS Kim, LJ Nastoupil, IW Flinn, M Shadman, C Diefenbach, CY Cheah, CY Ma, H Huang, A Kwan, MC Wei, S Yin, NL BartlettFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.